Up more 12,000% in a year, but is it really still good value?
This Covid-19 testing specialist has been a major winner from the pandemic. With the shares up over 12,000% in the past 12 months, can they really still be considered good value, as some contend? Our research into the phenomena that is Novacyt reflects on the facts, opportunities and risks.
Novacyt SA (LON:NCTR, PAR:ALNOV) is an international diagnostics group involved in the sale of diagnostic and pathogen testing kits based on molecular and protein testing technologies. We have followed the stock with interest in our regular Coronavirus updates, since February 2020 when we commented on Novacyt’s big break.
Sign up and read the full article
Register to continue reading our content.
Already a member? Login
Previous article Next article
For access to the top news and insights from the investment worldREGISTER FREE
More on Novacyt SA
After a volatile start to 2021, the share price of last year’s top AIM performer received…
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the…